Literature DB >> 6636046

Isolation and characterization of a hereditary abnormal antithrombin III 'Antithrombin III Toyama'.

T Koide, K Takahashi, S Odani, T Ono, N Sakuragawa.   

Abstract

A hereditary abnormal antithrombin III (AT-III) 'Antithrombin III Toyama' was purified from the plasma of a patient with recurrent thrombophlebitis by a procedure involving barium chloride and ammonium sulfate fractionations, affinity chromatography on anti-AT-III-Sepharose gel, and DEAE-Sephadex chromatography. Purified abnormal AT-III was shown to be the same as normal one in the molecular size, having the same molecular weight, amino-terminal sequence and carboxy-terminal amino acid. Abnormal AT-III gave the same UV spectrum as normal AT-III and both proteins were immunologically identical. Abnormal AT-III, however, showed the different electrophoretic mobility on agarose gel electrophoresis and immunoelectrophoresis. Abnormal AT-III was more electronegative than normal one, before and after a neuraminidase digestion of both proteins. These results suggest that in antithrombin III Toyama an amino acid residue at the heparin-binding site has been replaced by less basic or more acidic one which has no ability to interact with heparin, resulting in a loss of heparin cofactor activity of this protein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6636046     DOI: 10.1016/0049-3848(83)90334-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.

Authors:  T Koide; S Odani; K Takahashi; T Ono; N Sakuragawa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

2.  Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency.

Authors:  Seondeuk Kim; Woo-Jin Lee; Jangsup Moon; Keun-Hwa Jung
Journal:  Front Neurol       Date:  2022-06-03       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.